Trazher

Metastatic breast cancer in patients who have tumors that overexpress HER2 as monotherapy for the treatment of those patients who have received ≥1 chemotherapy regimens for their metastatic disease; in combination w/ paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease; & w/ an aromatase inhibitor for the treatment of postmenopausal patients w/ hormone-receptor +ve metastatic breast cancer, not previously treated w/ Trazher. HER2 +ve early breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) & RT (if applicable); & adjuvant chemotherapy w/ doxorubicin & cyclophosphamide, in combination w/ paclitaxel or docetaxel; in combination w/ adjuvant chemotherapy consisting of docetaxel & carboplatin; & w/ neoadjuvant chemotherapy followed by adjuvant Trazher therapy, for locally advanced (including inflammatory) disease or tumours >2 cm. In combination w/ capecitabine or 5-FU & cisplatin for patients w/ HER2 +ve stomach or gastro-esophageal junction metastatic adenocarcinoma who have not received prior anti-cancer treatment for their metastatic disease.

IV Metastatic breast cancer Initial loading dose: 4 mg/kg administered as a 90-min infusion. Subsequent doses: 2 mg/kg wkly. Can be administered as a 30-min infusion if prior dose was well tolerated. 3-wkly schedule: Initial loading dose: 8 mg/kg, followed by 6 mg/kg 3 wk later & then 6 mg/kg repeated at 3-wkly intervals administered as infusions over approx 90 min. Early breast cancer Initial loading dose: 8 mg/kg as 3-wkly regimen. Maintenance dose: 6 mg/kg at 3-wkly intervals, beginning 3 wk after the loading dose. Alternative wkly schedule: Initially 4 mg/kg followed by 2 mg/kg every wk) concomitantly w/ paclitaxel following chemotherapy w/ doxorubicin & cyclophosphamide. Metastatic gastric cancer Initial loading dose: 8 mg/kg, followed by 6 mg/kg 3 wk later & then 6 mg/kg repeated at 3-wkly intervals administered as infusions over approx 90 min. If the initial dose is well tolerated, the subsequent doses can be administered as a 30-min infusion.

Hypersensitivity to trastuzumab & murine proteins. Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.

Targeted Cancer Therapy

L01FD01 - trastuzumab ; Belongs to the class of HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors. Used in the treatment of cancer.

POM